| Effects of Risedronate in Bone Metabolism in Subacute Spinal Cord Injured Patients
-Report of Two Cases-
|
| 아급성 척수 손상 환자에서 Risedronate가
골 대사에 미치는 효과 -증례보고-
|
| 김상범,곽 현,손성근1,윤기성,이경우,이지혁2,류경현 |
| 동아대학교 의과대학 재활의학교실, 정형외과학교실1,
연세의료원 용인세브란스병원 심장내과2
|
|
|
| Abstract |
Objective
To assess the effect of risedronate in subacute Spinal cord injured patients.
Case 1: For 6 months, 61-year-old Spinal cord injuredman with a L1 ASIA A (duration: 5 months) took a vitamin D 500 ng and calcium gluconate 1500 mg daily and risedronate 35 mg weekly. In initial, his bone mineral density (BMD) was normal and serum osteocalcin (OC) level was borderline but urine deoxypyridinoline (u-DPD) level was markedly increased. After 6 months, u-DPD decreased about 46.5%.
Case 2: For 8 months, 51-year-old Spinal cord injuredman with a C6 central cord syndrome ASIA D (duration: 3 months) took same medication and evaluation as case 1. In initial, BMD was -3.7 in lumbar spine, -2.2 in left femur and -2.0 in right femur. u-DPD level was markedly increased but serum OC level was normal. After 8 months, lumbar spine and femoral neck BMD were improved and u-DPD level became normalized.
Conclusion
It is inadequate to make a conclusion with respect to evaluating the effects of risedronate on bone metabolism in subacute Spinal cord injured patients through two cases report, because it is unclear whether the obtained results reached statistical significance. Therefore, the results of this report may only recommend risedronate administration as to be trial to prevent bone loss caused by subacute spinal cord injury in clinical practice, and combined with the use of calcium and vitamin D.
|
| Key Words:
Spinal cord injured patients, Risedronate, BMD |
|
PDF Links
Full text via DOI
Download Citation
